19th Ave New York, NY 95822, USA

Team

Chief Executive Officer

Mike Solomon, Ph.D.

Chief Scientific Officer

Manjunath “Manju” Ramarao, Ph.D.

Chief Operating Officer & Chief Financial Officer

Barclay “Buck” Phillips

VP of RNA Biology

Katie Warner, Ph.D.

Senior Vice President, Drug Discovery

Ashis Saha, Ph.D.

Senior Director, Head of Biology

Charlie Holst, Ph.D.

Director, Head of Lead Discovery

Aaron Goetz, MS

Principal Scientist, Head of Assay development

Derek Parks

Senior Director, Head of Translational Medicine

Jessica Sorrentino, Ph.D.

Chief Executive Officer

Mike Solomon, Ph.D.

Mike has more than 20 years of experience in the biotechnology industry, with more than 17 focused on creating and operating early stage therapeutic-focused companies.

Mike served as Venture Partner at SV Health Investors where he led the seed round for Ribometrix before taking the CEO role. Previously, he served as chief operating officer at Decibel Therapeutics, a biotechnology company focused on broadly treating hearing disorders. Mike’s involvement at Decibel resulted from his role as an entrepreneur-in-residence at Third Rock Ventures, where he led the team that created Decibel’s business plan resulting in a $52 M Series A round.

Prior to Decibel, Mike was chief operating officer at Ember Therapeutics, a Third Rock Ventures company focused on obesity and diabetes, and chief business officer at Link Medicine, a neurodegeneration-focused biotechnology company that was sold to AstraZeneca. Mike was a founder and VP of discovery at Epizyme Therapeutics, a company focused on epigenetic modulators that is now a publicly traded company, and VP of discovery at Hypnion, Inc, a sleep disorder company that was sold to Lilly in 2007 for $325 million. Mike spent two years as a biotechnology analyst at Bank of America Securities. He started his career at Millennium Pharmaceuticals, where he was project leader for multiple programs.

Mike received his B.S. in chemistry from the University of Massachusetts, Amherst. He earned his Ph.D. in organic chemistry at the University of Wisconsin and completed postdoctoral work in synthetic organic chemistry at Scripps.

Chief Scientific Officer

Manjunath “Manju” Ramarao, Ph.D.

Manju has more than 20 years of experience biopharmaceutical research and development senior management and portfolio management.

Most recently, Manju held a senior executive position at the Biocon-Bristol-Myers Squibb R&D Center, BBRC, in Bangalore, India. He served as an executive director, site leader for research, and early development and head of discovery biology and translational medicine with responsibility for scientific strategy, a wide range of preclinical programs and platforms, and management of the large R&D organization. Research under his oversight spanned multiple therapeutic areas, including oncology, immunology, fibrosis, and cardiovascular disease. Manju joined Bristol-Myers Squibb and worked at BBRC since its inception in 2009. He was instrumental in building a world class research center with state-of-the-art capabilities and talent recruited from across the world.

Prior to his roles at BMS, Manju worked for eight years at Pfizer, Wyeth, in Cambridge, MA, leading biology programs in immunology and pain.
Manju received his B.Sc. and M.Sc. from Bangalore University, India, and his M.S. and Ph.D. from the University of Illinois. His post-graduate experience included a post-doctoral fellowship and an instructor position at Harvard Medical School.

Chief Operating Officer & Chief Financial Officer

Barclay “Buck” Phillips

Buck has more than 30 years of experience in biotech finance, business development, operations, and governance.

From 2008 to 2019, Buck served as the chief financial officer for three separate NASDAQ listed, development stage biotechnology companies; G1 Therapeutics, Novavax, and Micromet, acquired by Amgen in 2012 for $1.2 billion. In addition to his role as CFO, at G1 Therapeutics he also held the title of SVP, Corporate Development. During his tenure as CFO, Buck was responsible for all finance and accounting functions, financing strategy, successfully raising over $1.4 billion, Wall Street and investor relations, public relations, corporate strategy and corporate development.

Prior to his CFO roles, Buck had extensive experience in life science venture investing and public market investing, serving for nine years as the managing director of Vector Fund Management, a late-stage life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology, medical technology, and healthcare services companies. In addition, he was biotechnology analyst and director of venture Investments for INVESCO Funds group, a no-load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under management.

Buck received a Bachelor of Arts degree in economics from the University of Colorado, Boulder.

VP of RNA Biology

Katie Warner, Ph.D.

Katie co-founded Ribometrix with Kevin Weeks and was an early pioneer in SHAPE technologies, showing in 2009 with Dave Mathews and Kevin Weeks that SHAPE data can be used to model RNA secondary structure with high accuracy.

Katie continued her work with Adrian Ferré-D’Amaré and Chris Abell to show the first structure-based proof-of-principle that RNA is targetable by fragments. She has solved multiple RNA-small molecule crystal structures, including the fluorogenic RNAs “Spinach” and “Corn.”

Katie received a B.A. in chemistry from the University of North Carolina at Chapel Hill, and an M.Phil. in pathology and Ph.D. in chemistry from the University of Cambridge. Katie was a Beckman Scholar, a Churchill Scholar, an RNA Society/Scaringe awardee and an NIH-Oxford-Cambridge Scholar.

Senior Vice President, Drug Discovery

Ashis Saha, Ph.D.

Ashis brings more than 30 years of pharmaceutical medicinal chemistry, drug discovery, and entrepreneurial experience to Ribometrix.
Ashis comes to Ribometrix from Tarveda Therapeutics, where he served as Vice President of Chemistry and Lead discovery, with responsibility for all chemistry, biology, ADME, and in vivo screens.

Prior to Tarveda, Ashis was the founder and CSO of Dover Lifesciences, Vice President of TCG LifeSciences with responsibility for building an integrated drug discovery organization and leading drug discovery alliances and more than 65 internal and external chemists. Earlier in his career, Ashis worked in ascending roles at several biotechnology companies including Praecis Pharmaceuticals, VIROPHARMA, Janssen, and Sterling Winthrop.

His experience in medicinal chemistry is complemented by experience across many diseases area including oncology, rare diseases, autoimmune disorders, inflammation, Alzheimer’s, and Hepatitis-C, among others.

Ashis received his Ph.D. from the University of Michigan and his M.S. in Chemistry at ITT Kanpur, India.

Senior Director, Head of Biology

Charlie Holst, Ph.D.

Charlie has more than 15 years of experience in biopharmaceutical research and development. He brings both large pharma and small biotech perspective to Ribometrix, with therapeutic area experience in oncology, fibrosis, immunology/inflammation, and neuroscience

Most recently, Charlie held a Senior Director, Biology role at PTC and BioElectron Technology Corporation/Edison Pharmaceuticals, prior to its acquisition by PTC, in Mountain View, CA. Prior to that he spent several years at Pfizer’s San Francisco-located Center for Therapeutic Innovation, CTI, where he collaborated with leading academic physician scientists on novel therapeutic targets.

Charlie started his career as a Postdoctoral Fellow at Genentech before moving to the Molecular and Cellular Pharmacology group at Exelixis, contributing to multiple successful drug discovery projects.

Charlie earned his Ph.D. in Cell Biology studying early epigenetic alterations in breast cancer at the University of California in San Francisco and his BA in Biology from Lawrence University in Appleton, WI.

Director, Head of Lead Discovery

Aaron Goetz, MS

Aaron has more than 30 years of experience in biopharmaceutical research and development. Aaron’s history of experience in high-throughput screening and laboratory information management systems is an invaluable asset to the Ribometrix discovery platform, discovery programs and internal pipeline.

Prior joining Ribometrix, Aaron spent 30 years with GlaxoSmithKline, GSK, where he was a group leader and manager of a team focused on hit identification, hit validation and lead optimization. During his time at GSK, he worked on targets ranging from G-protein couple receptors, kinases and many others in disease areas ranging from oncology to metabolic disease and fibrosis.

Aaron received his BS in Biology/Chemistry from Kansas State and a Master’s degree in project management from New England College.

Principal Scientist, Head of Assay development

Derek Parks

Derek has more than 25 years of experience in designing, developing, and implementing assays for lead optimization, mechanism of action studies, and high-throughput screening. He leads the company in all activities related to new assay development to expand our understanding of RNA biology and function.

Prior to joining Ribometrix, Derek spent several years at Vitrisa Therapeutics as Biology Group Lead focused on RNA aptamer based ocular therapies, and at BioAgilytix leading a Bioanalytical group focused on large molecule therapies. Derek started his career in the biopharmaceutical industry with GlaxoSmithKline where he spent over 23 years and worked in numerous target class areas such as Nuclear Receptors, Kinases and Antivirals that spanned several disease areas including cancer, metabolic diseases, HIV, and hepatitis. Derek has authored and co- authored over 50 scientific papers and is an inventor on several patents.

Derek received his BS in Zoology and a BA in Chemistry from North Carolina State University.

Senior Director, Head of Translational Medicine

Jessica Sorrentino, Ph.D.

Jess brings a strong scientific background in biotechnology preclinical and clinical research and development in oncology.

Prior to joining Ribometrix, Jess was the Vice Preclinical of Translational Medicine at Istari Oncology supporting the development of an oncolytic virus for the treatment of multiple tumor indications including GBM, melanoma, and NMIBC. Additionally, Dr. Sorrentino was the Director of Translational Medicine and Biomarkers at G1Therapeutics where she led the translational program the three clinical-stage small molecule inhibitors including NDA approval of Trilaciclib in SCLC. Dr. Sorrentino has also served as an independent consultant working for other life science companies.

Dr. Sorrentino earned a PhD in toxicology from the University of North Carolina at Chapel Hill studying the role of chronic environmental toxicant exposure leading to both an advanced aging and tumorigenic phenotype Jess was also a Howard Hughes Scholar in the UNC Graduate Translational Medicine Training Program. Lastly, she earned her B.S. in Molecular Genetics from the University of Rochester in Rochester, NY.

Abha

“There is science in dance and art in science.” - Mae Jemison

Amanda

"You try and fail, try and fail, but the only true failure is when you stop trying.” – Albert Einstein

Andy

"My job is to bring clarity to a research enterprise increasingly defined by big data and help scientists move beyond the Excel spreadsheet"

Barry

“I enjoy finding appropriate roles for technology and gadgets in life and work”

Brittani

“Take chances, make mistakes, get messy.”-Ms. Frizzle, The Magic School Bus

Caleb

"Most of the shadows of this life are caused by standing in one's own sunshine." -Ralph Waldo Emerson

Chris

"Ask for help: that’s what separates the people who do things from those who just dream. You have to act and be willing to fail." Steve Jobs

Delita

“Never be limited by other people’s limited imaginations” – Dr. Mae Jemison

Denise

”You should never, never doubt something that no one is sure of.” - Roald Dahl

Devon

“We must understand the need for change. An unexamined life is not worth living.” – Marvin J. Ashton

Elizabeth

“The good thing about science is that it's true whether or not you believe in it.” - Neil deGrasse Tyson

Ericka

“Live each day to the fullest”

Holly

"People at Ribometrix work together toward the best possible solution."

Jamie

“If you want to change the world, start off by making your bed.” Admiral William H. McRaven

Jeff

“The moment you give up is the moment you let someone else win.” -Kobe Bryant

John

The saddest aspect of life right now is that science gathers knowledge faster than society gathers wisdom. ― Isaac Asimov

Jonathan

“Happiness is when what you think, what you say, and what you do are in harmony.”-Mahatma Gandhi

Karolina

“Remember, no matter where you go, there you are.”- Buckaroo Banzai

Krista

"'The strength of the team is each individual member. The strength of each member is the team." - Phil Jackson

LaShanda

“The soul of the sluggard craves and gets nothing, while the soul of the diligent is richly supplied” – King Solomon

Logan

“Science is a way of thinking much more than it is a body of knowledge” – Carl Sagan

Matt

“It’s only a model."

Matt

“Years ago, RNA was kind of a bit player...now we think RNA is really the important thing.” – Jack Szostak, Nobel Laureate

Melissa

“So, in the face of overwhelming odds, I'm left with only one option: I’m going to have to science the shit out of this.” The Martian

Melissa

"Somewhere, something incredible is waiting to be known." Carl Sagan

Mindy

“Choose a job you love, and you will never have to work a day in your life”. - Confucius

Monica

“There is a single light of science, and to brighten it anywhere is to brighten it everywhere.” – Isaac Asimov

Nick

”The world could always use more heroes”

Nicole

"If I have seen further, it is by standing upon the shoulders of giants" - Sir Isaac Newton

Patrick

“It is good to have an end to journey towards; but it is the journey that matters, in the end.” – Ursula K. Le Guin

Raquel

“At RBX I am always excited to collaborate with colleagues to tackle new challenges. I truly feel part of a great team!”

Roheeth

“If we knew what it was we were doing, it would not be called research, would it?” - Albert Einstein

Sarah

“Research is formalized curiosity. It is poking and prying with a purpose.” ― Zora Neale Hurston

Founder

Kevin Weeks, Scientific Advisor

William S. Marshall, Ph.D.

Joshua Mendell, Ph.D.

John Schneekloth, Jr., Ph.D.

Gene Yeo, Ph.D.

Founder

Kevin Weeks, Scientific Advisor

Kevin is a founder of Ribometrix and a Kenan Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill. The vision of his laboratory is to use chemical principles to explore the central role of RNA in biology with a focus on real-world problems and understanding human disease. RNA SHAPE technologies, invented in his laboratory, are used worldwide. The Weeks laboratory is applying SHAPE and other chemical technologies to challenging problems in biology, including the RNA-mediated reactions central to functions of mRNAs, lncRNAs, and viral RNAs.

Dr. Weeks obtained his BA with Honors and Department Honors in Chemistry from the College of Wooster and completed his Ph.D. at Yale, securing the Richard Wolfgang Prize for most Distinguished Dissertation in Chemistry. Dr. Weeks is a Fulbright and a Searle Scholar, an NIH EUREKA awardee, a Fellow of American Association for the Advancement of Science, a Life Member in Clare Hall at the University of Cambridge, and has taught many hundreds of undergraduates their first year chemistry.

William S. Marshall, Ph.D.

William S. Marshall, Ph.D., is an independent life sciences consultant to various biopharma companies, investors, foundations and academic institutions. Prior to that he was the President, Chief Executive Officer, Co-Founder and Director of miRagen Therapeutics, Inc. (NASDAQ: MGEN). miRagen discovered and developed a series on microRNA modulators, three of which demonstrated clinical proof of concept in the areas of hematological malignancy, fibrosis and induction of neo-angiogenesis. miRagen merged with Viridian Therapeutics in 2020. Prior to founding miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.

Joshua Mendell, Ph.D.

Dr. Joshua Mendell is a Howard Hughes Medical Institute Investigator, a Professor of Molecular Biology, and a member of the Harold C. Simmons Cancer Center and the Center for Regenerative Science and Medicine at the University of Texas Southwestern Medical Center, in Dallas, Texas.

Since 2004, Dr. Mendell has directed a research laboratory focused on investigating RNA biology in normal physiology and disease. In particular, the Mendell laboratory has devoted significant effort towards elucidating functions of noncoding RNAs, including microRNAs, miRNAs, and long noncoding RNAs, lncRNAs, and has made major contributions to our understanding of how these RNA transcripts contribute to diseases such as cancer.

For his work in this area, Dr. Mendell has been the recipient of several prestigious awards including the Allan C. Davis Medal for the Outstanding Young Scientist in the State of Maryland in 2007, the AACR Award for Outstanding Achievement in Cancer Research in 2010, and the O’Donnell Award from the Academy of Medicine, Engineering, and Science of Texas in 2016.

John Schneekloth, Jr., Ph.D.

John Schneekloth, Jr., Jay, is a Senior Investigator and head of the Chemical Genetics Section in the Center for Cancer Research at the National Cancer Institute, National Institutes of Health in Frederick, MD. Dr. Schneekloth has an A.B. in Chemistry from Dartmouth College, and a Ph.D. in Chemistry from Yale University. After a postdoctoral fellowship at Princeton University, he began his independent career at the NIH in 2011.

Dr. Schneekloth’s research focuses on chemical biology approaches to target RNA and DNA. The Schneekloth laboratory has pioneered the use of small molecule microarrays as a high throughput platform for the discovery and characterization of RNA-binding small molecules. His work has emphasized the discovery of new chemical and biophysical techniques to understand the selectivity and specificity of molecular interactions with nucleic acids. These efforts enable the development of chemical probes to investigate the role of RNA in diseases such as cancer. His research focuses on targeting challenging, therapeutically valuable nucleic acid targets in cancer such as MYC- and RAS-family genes. Dr. Schneekloth is also active within the research community, where he is currently Secretary of the ACS Division of Medicinal Chemistry

Gene Yeo, Ph.D.

Gene Yeo is a Professor of Cellular and Molecular Medicine at the University of California, San Diego, UCSD. Dr. Yeo has a BSc in Chemical Engineering and a BA in Economics from the University of Illinois, Urbana-Champaign, a Ph.D. in Computational Neuroscience from Massachusetts Institute of Technology and an MBA from the UCSD Rady School of Management. Dr. Yeo’s research interest is in understanding and manipulating RNA processing in development and disease using induced pluripotent stem cell and murine models. His lab demonstrated in vivo RNA targeting with CRISPR/Cas proteins with proof of concept in repeat expansion disorders. The Yeo research group members also developed enhanced CLIP for the purposes of large-scale mapping of protein-RNA interactions.

Gene’s lab is an active participant in RNA genomics technology and therapeutics development. Dr. Yeo is on the Editorial Boards of the journals Cell Reports and Cell Research. Dr. Yeo is a recipient of Alfred P Sloan Fellowship in recognition of his work in computational molecular biology (2011) and the inaugural Early Career Award from the International RNA Society (2017). Gene is a co-founder of several biotech companies including Locana, Eclipse Bioinnovations, Enzerna and Proteona. Gene serves or had served on the scientific advisory boards of the Allen Institute of Immunology, Locana, Eclipse Bioinnovations, Proteona, Aquinnah, LGC, Nugen and Ribometrix.

Chairman

Mike Clayman, MD

Chief Executive Officer

Mike Solomon, Ph.D.

Founder

Kevin Weeks, Scientific Advisor

Mike Ross, Ph.D.

John Gustofson, MBA

Mike Dial, Ph.D.

Hakan Goker, Ph.D.

William S. Marshall, Ph.D.

Chairman

Mike Clayman, MD

Mike Clayman, M.D., co-founded Flexion Therapeutics in 2007 and has since served as its president and CEO, guiding the discovery and development of ZILRETTA® for osteoarthritis-related knee pain. He also serves as chairman of the board of Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease.

Before founding Flexion, Dr. Clayman had a distinguished career at Eli Lilly and Company, leading numerous divisions engaged in a broad range of activities, from discovery research to clinical investigation to global regulatory affairs. Among his roles, he served as general manager of Chorus, Lilly’s early-phase development accelerator, and as vice president of Lilly Research Laboratories. Prior to Lilly, Dr. Clayman was an assistant professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease.

Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. He holds a B.A. from Yale University and an M.D. from the University of California, San Diego School of Medicine.

Chief Executive Officer

Mike Solomon, Ph.D.

Mike has more than 20 years of experience in the biotechnology industry, with more than 17 focused on creating and operating early stage therapeutic-focused companies.

Mike served as Venture Partner at SV Health Investors where he led the seed round for Ribometrix before taking the CEO role. Previously, he served as chief operating officer at Decibel Therapeutics, a biotechnology company focused on broadly treating hearing disorders. Mike’s involvement at Decibel resulted from his role as an entrepreneur-in-residence at Third Rock Ventures, where he led the team that created Decibel’s business plan resulting in a $52 M Series A round.

Prior to Decibel, Mike was chief operating officer at Ember Therapeutics, a Third Rock Ventures company focused on obesity and diabetes, and chief business officer at Link Medicine, a neurodegeneration-focused biotechnology company that was sold to AstraZeneca. Mike was a founder and VP of discovery at Epizyme Therapeutics, a company focused on epigenetic modulators that is now a publicly traded company, and VP of discovery at Hypnion, Inc, a sleep disorder company that was sold to Lilly in 2007 for $325 million. Mike spent two years as a biotechnology analyst at Bank of America Securities. He started his career at Millennium Pharmaceuticals, where he was project leader for multiple programs.

Mike received his B.S. in chemistry from the University of Massachusetts, Amherst. He earned his Ph.D. in organic chemistry at the University of Wisconsin and completed postdoctoral work in synthetic organic chemistry at Scripps.

Founder

Kevin Weeks, Scientific Advisor

Kevin is a founder of Ribometrix and a Kenan Distinguished Professor of Chemistry at the University of North Carolina at Chapel Hill. The vision of his laboratory is to use chemical principles to explore the central role of RNA in biology with a focus on real-world problems and understanding human disease. RNA SHAPE technologies, invented in his laboratory, are used worldwide. The Weeks laboratory is applying SHAPE and other chemical technologies to challenging problems in biology, including the RNA-mediated reactions central to functions of mRNAs, lncRNAs, and viral RNAs.

Dr. Weeks obtained his BA with Honors and Department Honors in Chemistry from the College of Wooster and completed his Ph.D. at Yale, securing the Richard Wolfgang Prize for most Distinguished Dissertation in Chemistry. Dr. Weeks is a Fulbright and a Searle Scholar, an NIH EUREKA awardee, a Fellow of American Association for the Advancement of Science, a Life Member in Clare Hall at the University of Cambridge, and has taught many hundreds of undergraduates their first year chemistry.

Mike Ross, Ph.D.

Michael Ross, Ph.D. serves as a Managing Partner of SV Life Sciences, SVLS. He was the tenth employee at Genentech, where he worked for 13 years in various roles including team leader and Vice President of Development. Dr. Ross also started Genentech’s protein engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the founding CEO of Arris Pharmaceutical, MetaXen, ExSAR and CyThera, now Novocell, and was also Managing Partner at Didyma, LLC, a biotechnology management consulting firm.

Dr. Ross currently serves or has served on the board of directors of several biotechnology companies, including Aderis Pharmaceuticals, Adimab, Alinea, Archemix, Arris Pharmaceuticals, Arsanis, Carta Proteomics, CyThera, Glycofi, Epimmune, Genencor, Ikano, Itero Biopharmaceuticals, Link Medicine, MetaXen, Mpex, NKT Therapeutics, Rempex, Rinat, Sutro Biopharmaceuticals and Xenova. He also serves on the faculty of Thayer School of Engineering at Dartmouth College.

Dr. Ross received his Bachelor of Arts, A.B., from Dartmouth College, his Doctor of Philosophy, Ph.D., degree in Chemistry from the California Institute of Technology, Caltech, and completed a Post-Doctorate program in Molecular Biology at Harvard University.

John Gustofson, MBA

John Gustofson is a Managing Director of AbbVie Ventures and invests across AbbVie’s therapy areas of Immunology, Oncology, and Neuroscience.

Prior to joining AbbVie, John worked at AstraZeneca as a Director of Strategic Partnering and Business Development focused on oncology licensing. John has 20+ years professional experience as a bench scientist and in various roles of market and business development. In addition John has worked in numerous biotechnology companies including Altus Pharmaceuticals, Therion Biologics, Boston Life Sciences and Ribozyme Pharmaceuticals. John also spent approximately 4 years in strategy consulting to the life sciences industry.

John holds a Master Degree in Molecular Biology from the Miami University and an MBA from the Boston University.

Mike Dial, Ph.D.

Experienced investor and scientist, Mike Dial has over a decade of experience working with early-stage life science and healthcare companies. Mike joined Hatteras in 2009 from Silicon Valley Bank, where he was a Vice President in the Corporate Finance Group focused on emerging tech and life science companies and venture capital funds. Prior to SVB, he held research scientist positions in the Department of Biochemistry at UNC-Chapel Hill, the Laboratory of Structural Biology at the National Institute of Environmental Health Sciences, and the UNC-Duke Michael Hooker Proteomics Center. He has performed research in the fields of cell cycle regulation, proteomics, and cancer therapy.

Mike is a Professor of the Practice at the Kenan-Flagler Business School at The University of North Carolina at Chapel Hill and is the Manager for the Carolina Research Ventures Fund, a $10M fund dedicated to UNC-Chapel Hill related start-ups. He holds a Ph.D. in Biochemistry and Biophysics from UNC-Chapel Hill.

Mike serves on the boards of Ribometrix, StrideBio, and Genturi and is a board observer at Spyryx. Previously, Mike was involved with G1 Therapeutics, Viamet, Lysosomal Therapeutics, Artizan Biosciences, and Curoverse among others, and has held various operational roles in Hatteras portfolio companies. Mike has also served on committees and panels for the North Carolina Biotech Center, Council for Entrepreneurial Development, SEBIO and PTP NEXT.

Hakan Goker, Ph.D.

Hakan Goker, Ph.D., is a senior investment director at M Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan has been investing for the past 12 years and joined M Ventures in 2013. Previously Hakan was a partner at Aescap Venture and prior to that was part of Atlas Venture life sciences team.

Since 2006, Hakan has been instrumental in the creation, financing, and corporate strategy of multiple biotechnology companies globally including Artios, Asceneuron, Storm, Bicycle, and F-star. Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan currently is a board member at Artios Pharma, Asceneuron, Forendo, Macrophage Pharma, Ribometrix Inc., Storm Therapeutics, Synaffix, Tocopherx, and is the chairperson of iOnctura.

William S. Marshall, Ph.D.

William S. Marshall, Ph.D., is an independent life sciences consultant to various biopharma companies, investors, foundations and academic institutions. Prior to that he was the President, Chief Executive Officer, Co-Founder and Director of miRagen Therapeutics, Inc. (NASDAQ: MGEN). miRagen discovered and developed a series on microRNA modulators, three of which demonstrated clinical proof of concept in the areas of hematological malignancy, fibrosis and induction of neo-angiogenesis. miRagen merged with Viridian Therapeutics in 2020. Prior to founding miRagen, Dr. Marshall was Vice President of Technology and Business Development for Bioscience at Thermo Fisher Scientific. In this role, he was responsible for leading technology assessment and strategic planning for the Thermo Fisher Biosciences Division, a unit with revenues of approximately $1 billion that manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas.

Dr. Marshall was one of the scientific founders of Dharmacon, Inc., which was acquired by Fisher Scientific International, serving as the Executive Vice President for Research and Operations and General Manager. Prior to joining Dharmacon, Dr. Marshall served in many capacities at Amgen, Inc., most recently as Associate Director of Research, Site Head for Research and Head of the Nucleic Acid and Peptide Technology Department. In these positions, he participated in a wide variety of therapeutic development approaches throughout the drug discovery process leading to the development of clinical candidates.

Dr. Marshall earned his B.S. in Biochemistry from the University of Wisconsin-Madison and his Ph.D. in Chemistry in the laboratory of Professor Marvin Caruthers at the University of Colorado at Boulder. He is author and co-author of over 50 research papers and 80 patents. Dr. Marshall currently serves on the Board of FluoroFinder, LLC.